Tokyo, December 13, 2013 - Astellas Pharma Inc. (“Astellas”; headquarters : Tokyo:4503; President and CEO: Yoshihiko Hatanaka), today announced that a definitive agreement has been concluded between Astellas Pharma Tech Co., Ltd. (“Astellas Pharma Tech”; headquarters: Tokyo; President : Takashi Shimizu), Astellas’ production subsidiary in Japan, and Nichi-Iko Pharmaceutical Co., Ltd. (“Nichi-Iko”; headquarters : Toyama; President and CEO: Yuichi Tamura), under which Nichi-Iko will succeed to the business of Fuji Plant (Fuji-shi, Shizuoka), one of production sites of Astellas Pharma Tech on April 1, 2014 by Company Split.

Astellas and Nichi-Iko has entered into a basic agreement as announced on September 27, 2013.
https://www.astellas.com/jp/en/news/11576

#######

Contact the Media Relations team
Corporate Advocacy & Relations
Main phone line for Media: +81-3244-3201 
Business hours (JST)
From Monday to Thursday: 8:45 am to 5:45 pm, Friday: 8:45 am to 4:00 pm
(closed on Saturdays, Sundays, national holidays and company holidays)